ASCO 2013: Weekend Presentation Review (3rd June)
Review the key highlights from this weekend’s presentations at the American Society of Clinical Oncology Annual Meeting (ASCO), using this complimentary Analysis Update from our intelligence partners...
View ArticleASCO 2013: AstraZeneca U-turns on olaparib after retrospective analysis
A retrospective analysis of Phase II data has indicated that the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib may be effective as a treatment for advanced ovarian cancer patients with...
View ArticlePodcast: Post ASCO 2013 Review
Following this year’s American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago, join experts from Scrip Intelligence and Datamonitor Healthcareto review some of the key event findings and...
View ArticleASCO 2013: Positive Phase III data for T-VEC gives Amgen strong approval outlook
On June 1, 2013, Dr Robert Andtbacka presented the results of T-VEC’s (talimogene laherparepvec; Amgen) Phase III clinical trial for unresected Stage IIIB/C and IV melanoma. T-VEC met the primary...
View ArticleASCO 2013: PD-1 and PD-L1 inhibitors – the next-gen immunotherapies
ASCO 2013 saw Bristol-Myers Squibb, Merck & Co, and Roche present updated and new data on their PD-1 and PD-L1 inhibitors. The data presented show that the competition between these three drugs...
View ArticlePodcast: What future for the PARP inhibitors as candidates experience mixed...
Join our experts for a short discussion on the future of the PARP inhibitors, a potential new class of anticancer agents that are back in the spotlight following the ASCO meeting. Your expert hosts for...
View ArticleASCO 2015: Post-Conference Roundtable
With this year’s ASCO conference over for another year, we thought it would be worthwhile to get Informa’s experts together again to discuss the key takeaways from this year’s conference, assess its...
View ArticleAn ASCO Primer: Which Drug Makers are Pursuing Which Kinds of Therapies
Datamonitor Healthcare was proud to assist the Wall Street Journal in compiling a fascinating article on cancer immunotherapy. You can read a quick extract below, but make sure you click to read the...
View ArticleCancer breakthroughs trigger big pharma interest in drugs and deals
Datamonitor Healthcare is proud to be featured in the Guardian’s fascinating new article on cancer immunotherapy. You can read a quick extract below, but make sure you click to read the full article –...
View ArticleASCO 2015 Conference Review
With ASCO over for another year we’ve put together an overview of key highlights from this year’s conference. Our NEW white paper allows you to read through the results and implications of these key...
View Article
More Pages to Explore .....